Roche Launches Elecsys PRO-C3 Test To Detect Liver Fibrosis Severity In MASLD Patients

Roche has introduced the Elecsys® PRO-C3 test, a new diagnostic tool to assess the severity of liver fibrosis in patients with metabolic dysfunction–associated steatotic liver disease (MASLD). Developed with Nordic Bioscience, the test enables clinicians to evaluate fibrosis levels quickly and accurately, helping to guide timely intervention and treatment decisions for this increasingly common liver condition.

Matt Sause, CEO of Roche Diagnostics, stated, "The Elecsys PRO-C3 test addresses an urgent need in the diagnosis, staging and management of liver fibrosis. With MASLD affecting a growing number of people worldwide and new treatments emerging, it is critical to detect fibrosis accurately and early. Our innovative solution simplifies the diagnostic process and eases the burden on healthcare services, providing a clear and rapid assessment while reducing the requirement for invasive biopsies."

MASLD, linked to diabetes, obesity, and other cardiometabolic factors, affects nearly 30% of the global population and often remains undiagnosed until late-stage liver damage. As new drug therapies emerge for treating fibrosis, the ability to detect and classify disease severity becomes crucial. The Elecsys PRO-C3 test supports this shift by measuring a biomarker associated with fibrogenesis and delivering results in just 18 minutes on Roche’s cobas® systems.

Used alongside the ADAPT formula, which incorporates PRO-C3 levels, platelet count, age, and diabetes status, the test helps distinguish between key fibrosis stages (≥F2, ≥F3, and F4). The initial calculation of ADAPT scores will be handled manually until Roche rolls out automated software during the last part of 2025. The innovation offers doctors a tool which aims to simplify diagnosis and cut costs while improving access to customised care for people with potential liver disease progression.